The PDUFA target action date is in the fourth quarter of 2026.
Feature|Articles|September 25, 2025
ESMO 2025 preview: Key late-breaking abstracts in genitourinary oncology
Fact checked by: Hannah Clarke
Take a closer look at what urologists can expect from the LBAs that will headline ESMO 2025.
Advertisement
Advertisement
As the final quarter of 2025 comes into view, the calendar is filling with important scientific gatherings that will shape the next wave of urology practice and research. Among these, the European Society for Medical Oncology (ESMO) Congress has become one of the most anticipated fall meetings, particularly for clinicians and researchers focused on cancer care.
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Advertisement
Advertisement